Selected Publications

Translational Genetics

2018

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. - Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT. - 2018 - Nat Commun - PubMed

2017

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. - Brown D, Smeets D, Székely B, Larsimont D, A Szász M, Adnet P-Y, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés A-M, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C - 2017 - Nat Commun. - PubMed

The role of fatty acid Beta-oxidation in lymphangiogenesis. - Wong BW, Wang X, Zecchin A, Thienpont B, Cornelissen I, Kalucka J, García-Caballero M, Missiaen R, Huang H, Bruning U, Blacher S, Vinckier S, Goveia J, Knobloch M, Zhao H, Dierkes C, Shi C, Hägerling R, Moral-Dardé V, Wyns S, Lippens M, Jessberger S, Fendt S-M, Luttun A, Noël A, Kiefer F, Ghesquière B, Moons L, Schoonjans L, Dewerchin M, Eelen G, Lambrechts D, Carmeliet P. - 2017 - Nature - PubMed

2016

Tumour hypoxia causes DNA hypermethylation by reducing TET activity. - Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, Ghesquière B, Van Dyck L, Boeckx B, Schoonjans L, Hermans E, Amant F, Kristensen VN, Koh KPeng, Mazzone M, Coleman ML, Carell T, Carmeliet P, Lambrechts D. - 2016 - Nature - PubMed

HIF-1alpha Promotes Glutamine-Mediated Redox Homeostasis and Glycogen-Dependent Bioenergetics to Support Postimplantation Bone Cell Survival. - Stegen S, Van Gastel N, Eelen G, Ghesquière B, D'Anna F, Thienpont B, Gouveia J, Torrekens S, Van Looveren R, Luyten FP, Maxwell PH, Wielockx B, Lambrechts D, Fendt S-M, Carmeliet P, Carmeliet G. - 2016 - Cell Metab - PubMed

2015

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. - Lambrechts D, Thienpont B, Thuillier V, Sagaert X, Moisse M, Peuteman G, Pericay C, Folprecht G, Zalcberg J, Zilocchi C, Margherini E, Chiron M, Van Cutsem E. - 2015 - Br J Cancer - PubMed

Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. - Nassar D, Latil M, Boeckx B, Lambrechts D, Blanpain C. - 2015 - Nat Med. - PubMed

2013

Markers of response for the antiangiogenic agent bevacizumab - Lambrechts D, Lenz H-J, de Haas S, Carmeliet P, Scherer SJ. - 2013 - J Clin Oncol - PubMed

2012

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. - Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E. - 2012 - Lancet Oncol - PubMed

2011

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. - Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, Van Loo P, Van Den Bossche M, Catthoor K, Sabbe B, Despierre E, Vergote I, Hilbush B, Lambrechts D, Del-Favero J. - 2011 - Nat Biotechnol - PubMed